Letters Section Editor: Stephen J. Lurie,
MD, PhD, Senior Editor.
In Reply: In response to Dr Frieden and colleagues,
we point out that the prevalences of congenital anomalies in the group treated
with CART and the control group were not significantly different from one
another (5.6% vs 1.7%, P = .09), whereas a significant
difference was found in the prevalence of hemangiomas (4.2% vs 0.3%, P = .02). We selected a contemporary control group exposed
to nonteratogenic drugs because, considering the importance of this therapy
during pregnancy, a contemporary HIV-positive group not exposed to retroviral
drugs was not available. Our 3 cases of hemangioma were found in 3 male infants,
of whom only 1 was born prematurely (gestational age, 36 weeks). The case
from among the control group was a female infant born at term of pregnancy.
De Santis M, Cavaliere AF, Caruso A, Villa P, Tamburrini E, Cauda R, Fundaro C, Genovese O. Combined Antiretroviral Therapy During Pregnancy and Risk of Congenital Malformations—Reply. JAMA. 2004;291(16):1961-1962. doi:10.1001/jama.291.16.1962